Editorial comment on: The surgical management of paediatric bladder and prostate rhabdomyosarcoma

IV. The Children’s Oncology Group. J Clin Oncol 2006;24: 3844–51. [6] Ortega JA, Rowland J, Monforte H, Malogolowkin M, Triche T. Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: implications for outcome. J Pediatr Hematol Oncol 2000;22:106–11. [7] Arndt CAS, Hammond S, Rodeberg D, Qualman S. Significance of persistent mature rhabdomyoblasts in bladder/prostate rhabdomyosarcoma. Results from IRS IV. J Pediatr Hematol Oncol 2006;28:563–7. [8] Ferrer FA, Isakoff M, Koyle MA. Bladder/prostate rhabdomyosarcoma. Past, present, and future. J Urol 2006;176:1283–91. [9] Joshi D, Anderson JR, Paidas C, Breneman J, Parham DM, Crist W. Age is an independent prognostic factor in rhabdomyosarcoma. A report from the Soft Tissue Sarcoma committee of the Children’s Oncology Group. Pediatr Blood Cancer 2004;42:64–73. [10] Children’s Oncology Group ARST0531. [11] Walterhouse D, Watson A. Optimal management strategies for rhabdomyosarcoma in children. Pediatr Drugs 2007;9:391–400. [12] Raney Jr RB, Gehan EA, Hays DM, Tefft M, Newton Jr WA, Haeberlen V, et al. Primary chemotherapy with or without radiation therapy and/or surgery for children with localized sarcoma of the bladder, prostate, vagina, uterus, and cervix. A comparison of the results in Intergroup Rhabdomyosarcom Studies I and II. Cancer 1990;2072–81. [13] Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610–30. [14] Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2000;18: 2427–34. [15] Crist WM, Anderon JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup Rhabdomyosarcoma Study-IV. Results for patients with nonmetastatic disease. J Clin Oncol 2001;19: 3091–102. [16] Donaldson SS, Meza J, Breneman JC, Crist WM, Laurie F, Qualman SJ, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma – a report from the IRSG. Int J Radiat Oncol Biol Phys 2001;51:718–28. [17] Koscielniak E, Harms D, Henze G, Jurgens H, Gadner H, Herbst H, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 1999;12:3706–19. [18] Flamant F, Rodary C, Rey A, Praquin MT, Sommelet D, Quintana E, et al. Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology MMT 84. Eur J Cancer 1998;34:1050–62. [19] Stevens MCG, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89. J Clin Oncol 2005;23:2618–28. [20] Oberlin O, Rey A, de Toledo JS, Martelli H, Jenney MEM, Scopinaro M, et al. Randomized comparison of intensified sixdrug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. J Clin Oncol 2012;20:2457–65. [21] Raney B, Anderson J, Jenney M, Arndt C, Brecht I, Carli M, et al. Late effects in 164 patients with rhabdomyosarcoma of the bladder/prostate region: a report from the International Workshop. J Urol 2006;176:2190–5. [22] Arndt C, Rodeberg D, Breitfeld PP, Raney RB, Ullrich F, Donaldson S. Does bladder preservation (as a surgical principle) lead to retaining bladder function in bladder/prostate rhabdomyosarcoma? Results from Intergroup Rhabdomyosarcoma Study IV. J Urol 2004;171:2396–403. [23] Stevens MCG. Treatment for childhood rhabdomyosarcoma: the cost of cure. Lancet Oncol 2005;6:77–84. [24] Wu HY, Snyder HM, Womer RB. Genitourinary rhabdomyosarcoma: which treatment, how much, and when? J Pediatr Urol 2009;5:501–6. [25] Seitz G, Dantonello TM, Int-Veen C, Blumenstock G, Godzinski T, Klingebiel T, et al. Treatment efficiency, outcome and surgical treatment problems in patients suffering from localized embryonal bladder/prostate rhabdomyosarcoma: a report from the Cooperative Soft Tissue Sarcoma Trial CWS-96. Pediatr Blood Cancer 2011;56:718–24. [26] Martelli H, Maie-Meder C, Branchereau S, Franchi-Abella S, Ghigna M-R, Dumas I, et al. Conservative therapy plus brachytherapy for boys with prostate and/or bladder neck rhabdomyosarcoma: a single team experience. J Pediatr Surg 2009;44: 190–6. [27] Yeung CK, Ward HC, Ransley PG, Duffy PG, Pritchard J. Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood. Br J Cancer 1994;70:1000–3. [28] Soler R, Macedo Jr A, Bruschini H, Puty F, Caran E, Petrilli A, et al. Does the less aggressive multimodal approach of treating bladder-prostate rhabdomyosarcoma preserve bladder function? J Urol 2006;174:2343–6. [29] Raney Jr B, Heyn R, Hays DM, Tefft M, Newton WA, Wharam M, et al. Sequelae of treatment in 109 patients followed for 5– 15 years after diagnosis of sarcoma of the bladder and prostate. Cancer 1993;71:2387–94. [30] Hays DM, Raney RB, Wharam MD, Wiener E, Lobe TE, Andrassy RJ, et al. Children with vesical rhabdomyosarcoma (RMS) treated by partial cystectomy with neoadjuvant or adjuvant chemotherapy, with of without radiotherapy. J Pediatr Hematol Oncol 1995;17:46–52. [31] Raney B, Stoner J, Anderson J, Andrassy R, Arndt C, Brown K, et al. Impact of tumor viability at second-look procedure before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV 1991–97: a report from the Children’s Oncology Group. J Pediatr Surg 2010;45:2160–8. [32] Ricard F, Cimarelli S, Deshayes E, Mognetti T, Thiesse P, Giammarile F. Additional benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 2011;36:672–7. [33] Meyer WH. Playing bad cards properly: challenges to improving cure rates in rhabdomyosarcoma. J Clin Oncol 2012;20:2431–3.